Age Range
40 - 85
Trial Purpose
Abacwaningi bafuna izindlela zokwelapha i-pulmonary hypertension (PH) ebangelwa yi-chronic obstructive pulmonary disease (COPD). Umgomo wocwaningo ukufunda ukuthi abantu abathatha i-frespaciguat bangakwazi yini ukuhamba ibanga elide emizuzwini engu-6 ngeviki lama-24 uma kuqhathaniswa nabantu abathatha i-placebo.
NATIONAL TRIAL REFERENCE NUMBER
I-NCT05612035
EudraCT
2022-501201-13-00
EU CT Number
2022-501201-13-00
When speaking to your doctor or clinical trial representative, please have the trial reference number available.
About The Study
Trial Phase
Trial start and end dates
- Actual study start date Mashi 16, 2023
- Estimated primary completion date Ephreli 7, 2026
- Estimated study completion date Okthoba 7, 2029
Trial locations
Sorry, there are no locations found.